Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 2
Submit an article Journal homepage
206
Views
1
CrossRef citations to date
0
Altmetric
Review

Immunotherapy of Chronic Myeloid Leukemia: Present State and Future Prospects

Vladimír VonkaDepartment of Experimental Virology, Institutute of Hematology & Blood Transfusion, U nemocnice 1, 128 20 Prague 2, Czech Republic. Tel.: +420 221 977 383 Fax: +420 221 977 [email protected]View further author information
Pages 227-241 | Published online: 05 Mar 2010

Bibliography

  • Buchdunger E , CioffiCL, LawNet al.: Abl protein-tyrosine kinase inhibitor ST171 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.J. Pharmacol. Exp. Ther.295 , 137–145 (2000).
  • Druker BJ , GuilhotF, O‘BrienSGet al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.N. Engl. J. Med.355 , 2408–2417 (2006).
  • Druker BJ , SawyersC, KantarjianHet al.: Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblasti leukemia with the Philadelphia chromosome.N. Engl. J. Med.344 , 1038–1042 (2001).
  • le Coutre P , TassiE, Varella-GarciaMet al.: Induction of resistence to the Abelson inhibitor ST1571 in human leukemic cells through gene amplification.Blood95 , 1758–1766 (2000).
  • Hochhaus A , KreilS, CorbinASet al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.Leukemia16 , 2190–2196 (2002).
  • Azam M , DaleyGQ: Anticipating clinical resistance to target-directed agents: the BCR–ABL paradigm.Mol. Diagn. Ther.10 , 67–76 (2006).
  • Shah NP , TranNP, LeeFYet al.: Overriding imatinib resistence with a novel ABL kinase inhibitor.Science305 , 399–401 (2004).
  • Weisberg E , ManleyPW, BreitenstreinWet al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr–Abl.Cancer Cell7 , 129–141 (2005).
  • Seggewiss R , PriceDA, PurbhooMA: Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update.Cytotherapy10 , 633–641 (2008).
  • Berke Z , AndersenMH, PedersenM, FuggerL, ZeuthenJ, HaurumJS: Peptides spanning the junctional region of both the bcr–abl fusion proteins bind common HLA class I molecules.Leukemia14 , 419–426 (2000).
  • Pittet MJ : Behaviour of immune players in the tumor microienvirnoment.Curr. Opin. Oncol.21 , 2153–2159 (2009).
  • Stewart TJ , AbramsSI: How tumours escape mass destruction.Oncogene27 , 5894–5903 (2008).
  • Bronte V , MocellinS: Suppressive influences in the immune response to cancer.J. Immunother.32 , 1–11 (2009).
  • Biernaux C , LoosM, SelsA, HuezG, StryckmansP: Detection of major bcr–abl gene expression at a very low level in blood cells of some healthy individuals.Blood86 , 3118–3122 (1995).
  • Bose S , DeiningerM, Gora-TyborJ, GoldmanJM, MeloJV: The presence of typical and atypical BCR–ABL fusion genes in leukocytes of normal individuals: biologic significance and implication for the assessment of minimal residual disease.Blood92 , 3362–3367 (1998).
  • Posthuma EF , FalkenburgJH, ApperleyJFet al.: HLA-B8 and HLA-A3 coexpressed with HLA B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBHT.Blood93 , 3863–3865 (1999).
  • Khosravi F , AmirzargarA, SarafnejadA et al: HLA class II allele and haplotype frequencies in Iranian patients with leukemia. Iran J. Allergy Asthma Immunol.6 , 137–142 (2007).
  • Naugler C , LiwskiR: HLA risk markers for chronic myelogenous leukemia in eastern Canada.Leuk. Lymphoma50 , 254–259 (2009).
  • Chakrabarti D , HultgrenB, StewartTA: IFN-α induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2.J. Immunol.157 , 522–528 (1996).
  • Molldrem JL , LeePP, WangC et al: Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med.6 , 1018–1023 (2000).
  • Burchert A , WolflS, SchmidtMet al.: Interferon-α but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and specific T-cell response in chronic myeloid leukemia.Blood101 , 259–264 (2003).
  • Gabriele L , BorghiP, RozeraCet al.: IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment.Blood103 , 980–987 (2004).
  • Collins RH Jr, Spilberg O, Drobyski WR et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol.15 , 433–434 (1997).
  • Norde WJ , OveresIM, MaasFet al.: Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.Blood113 , 2312–2323 (2009).
  • Bocchia M , WentworthPA, SouthwoodSet al.: Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.Blood85 , 2680–2684 (1995)
  • Bocchia M , KorontsvitT, XuQ et al: Specific human cellular immunity to bcr-abl oncogene derived peptides. Blood87 , 3587–3592 (1996).
  • ten Bosch GJ , JoostenAM, KesslerJH, MeliefCJ, LeeksmaOC: Recognition of BCR–ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR–ABL breakpoint peptides.Blood88 , 3522–3527 (1996)
  • ten Bosch GJ , ToornvlietAC, FriedeT, MeliefCJ, LeeksmaOC: Recognition of peptides corresponding to the joining region of p210BCR–ABL protein by human T cells.Leukemia9 , 1344–1348 (1995).
  • Pawelec G , MaxH, HalderTet al.: BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found in low frequency in the repertoire of normal donors.Blood88 , 2118–2124 (1996).
  • Osman Y , TakahashiM, ZhengZet al.: Generation of bcr-abl-specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its application for donor leukocyte transfusions in marrow grafted CML patients.Leukemia13 , 166–174 (1999).
  • Pinilla-Ibarz J , CathcartK, ScheinbergDA: CML vaccines as a paradigm of the specific immunotherapy of cancer.Blood Rev.14 , 11–20 (2000).
  • Yotnda P , FiratP, Garcia-PonsFet al.: Cytotoxic T cells response against the chimeric p210 BCR–ABL protein in patients with chronic myelogenous leukaemia.J. Clin. Invest.101 , 2290–2296, (1998).
  • Clark RE , DodiIA, HillSCet al.: Direkt evidence that leukemic cells present HLA-associated immunogenic peptides derived from BCR–ABL b3a2 fusion protein.Blood98 , 2887–2893 (2001).
  • Wagner WM , OuyangQ, PawelecG: The abl-bcr gene product as a novel leukemia specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.Cancer Immunol. Immunother.52 , 89–96 (2003).
  • Gannagé M , AbelM, MichalletASet al.: Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.J. Immunol.174 , 8210–8218 (2005).
  • El-Shami K , SmithBD: Immunotherapy for myeloid leukemias: current status and future directions.Leukemia22 , 1658–1664 (2008).
  • Grünebach F , MirakajV, MirakajV, MillerMR, BrümmendorfT, BrossartP: BCR–ABL is not an immunodominant in chronic myeloid leukemia.Cancer Res.66 , 5892–5900 (2006)
  • Brauer KM , WerthD, von Schwarzenberg K et al.: BCR–ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res.67 , 5489–5497 (2007)
  • Scheich F , DuysterJ, PeschelC, BernhardtH: The immunogenicity of Bcr–Abl-expressing dendritic cells is dependent on the Bcr–Abl kinase activity and dominated by Bcr–Abl-regulated antigens.Blood110 , 2556–2560 (2007).
  • Witko-Sarsat V , CanteloupS, DurantSet al.: Cleavage of p21waf1 by proteinase 3, a myeloid-specific serine protease, potentiates cell proliferation.J. Biol. Chem.277 , 47338–47347 (2002).
  • El-Ouriaghli F , SloandE, MainwaringL, FujiwaraH, KeyvanfarK, MelenhorstJJ: Clonal dominance of chronic myelogenous leukaemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastaseBlood15 , 3786–3792 (2003).
  • Wilson TJ , NannuruKC, SinghRK: Cathepsin G recruits osteoclast precursors via proteolytic activation of protease-activated receptor-1.Cancer Res.69 , 3186–3195 (2009).
  • Reed JC , PelecchiaM: Apoptosis-based therapies for hematologic malignancies.Blood106 , 408–418 (2005).
  • Lam JS , PantucAJ, BelldegrunAS, FiglinRA: G 250: a carbonic anhydrase IX monoclonal antibody.Curr. Oncol. Rep.7 , 109–115 (2005).
  • Beatty GL , VonderheideRH: Telomerase as a universal tumor antigen for cancer vaccines.Expert Rev. Vaccines7 , 881–887 (2008).
  • Resto VA , CaballeroOL, ButaMRet al.: A putative oncogenic role for MPP11 in head and neck squamous cell cancer.Cancer Res.60 , 5529–5535 (2000).
  • Scanlan MJ , SimpsonJG, OldLJ: The cancer/testis genes: review, standardization and commentary.Cancer Immunol.4 , 1–13 (2004).
  • Oehler VG , GuthrieKA, CummingsCLet al.: The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematotopoietic and leukemic progenitor cells.Blood114 , 3299–3308 (2009).
  • van Baren N , ChambostH, FerrantAet al.: PRAME, a gene encoding an antigen recognized in human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.Br. J. Haematol.102 , 1376–1379 (1998).
  • Reiter R , GaisP, JüttingUet al.: Aurora-kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma.Clin. Cancer Res.12 , 5136–5141 (2006).
  • Yang XF , WuCJ, ChenLet al.: CML 28 is broadly immunogenic antigen, which is expressed in tumor cells.Cancer Res.62 , 5517–5522 (2002).
  • Wang Q , LiM, WangYJ et al: RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of Hela cells. Cancer Lett.269 , 127–138 (2008).
  • Schmidt SM , SchagK, MullerMR et al: Induction of adipophilin-specific cytotoxic lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res.64 , 1164–1170 (2004).
  • Shin S , SungBJ, ChoYS et al: An anti-apoptotic protein human survivin is direct inhibitor of caspase-3 and -7. Biochemistry40 , 1117–1123 (2001).
  • Carter BZ , MakDH, SchoberWD et al: Regulation of survivin expression through Bcr–Abl/MARK cascade: targeting survivin overcomes imatinib resistence and increases imatinib sensitivity in imatinib-responsive CML cells. Blood107 , 1555–1563 (2006).
  • Postel EH , BerberichSJ, RooneyJW, KaetzelDM: Human NM23-H2 nucleoside diphosphate kinase regulates gene expression through DNA binding to nuclease-hypersensitive transcriptional elements.J. Bioenerg. Biomembr.32 , 277–284 (2000).
  • Greiner J , SchmittM: Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.Eur. J. Haematol.80 , 461–468 (2008).
  • Mumprecht S , SchurchC, SchwallerJ, SolenthalerM, OchsenbeinAF: Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T cell exhaustion and disease progression.Blood114 , 1528–1536 (2009).
  • Papallardo F , PennisiM, CastiglioneF, MottaS: Vaccine protocols optimization: in silico experiments.Biotechnol. Adv.28 , 82–93 (2100).
  • Gowthaman U , AgrewalaJN: In silico methods for predicting the cell epitopes: Dr Jekyll or Mr Hyde?Expert Rev. Protomics6 , 527–537 (2010).
  • He L , FengH, RaymondA et al: Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol. Immunother.50 , 31–40 (2001).
  • Kislin KL , MarronMT, LiG, GranerMW, KatsanisE: Chaperone-rich cell lysate embedded with BCR–ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR–ABL positive leukemia.FASEB J.21 , 2173–2184 (2007).
  • Krause DS , Van Etten RA: Adoptive immunotherapy of BCR–ABL- induced chronic myeloid leukemia-like myeloproliferative disease in a murine model Blood, 104 , 4236–4244 (2004).
  • Ling X , WangY, DietrichMF, AndreeffM, ArlinghausRB: Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.Oncogene25 , 4483–4490 (2006).
  • Deeb D , GaoX, JiangH, DivineG, DulchavskySA, GautamBC: Vaccination with leukemia-loaded dendritic cells eradicates residual diseases and prevent relapse.J. Exp. Ther. Oncol.5 , 183–193 (2006).
  • McLaughlin J , ChianeseE, WitteON: In vitro transformation of immature haematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.Proc. Natl Acad. Sci USA84 , 6558–6562 (1987).
  • Daley GQ , BaltimoreD: Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukaemia-specific P210bcr/abl protein.Proc. Natl. Acd. Sci. USA85 , 9312–9316 (1988).
  • Sobotková E , LudvíkováV, PetráčkováMet al.: Characteristics of two mouse bcr-abl-transformed cell lines I. General properties of the cells.Folia Biol. (Praha)51 , 12–18 (2005).
  • Jelínek F , SobotkováE, VonkaV: Characteristics of two mouse bcr-abl-transformed cell lines. II. Pathological lesions induced in mice.Folia Biol. (Praha)51 , 93–102 (2005).
  • Lucanský V , SobotkováE, TachezyR, DuškováM, VonkaV: DNA vaccination against bcr-abl- transfornmed cells in mice.Int. J. Oncol.35 , 941–951 (2009).
  • Hrušková V , MorávkováA, BabiarovaK et al: Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles. Int. J. Oncol.35 , 1247–1256 (2009).
  • Petráčková M , SobotkováE, DuškováM, JinochP, VonkaV: Isolation and properties of gene-modified mouse bcr–abl-transformed cells expressing various immunostimulatory factors.Neoplasma56 , 194–201 (2009).
  • Sobotková E , DuškováM, TachezyR, PetrackovaM, VonkaV: Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells.Oncol. Rep.21 , 793–799 (2009).
  • Orsini E , CalabreseE, MaggioRet al.: Circulating myeloid dendritic cells directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr–abl translocation.Leuk. Res.30 , 785–794 (2006).
  • Mumprecht S , ClausC, SchürchCH, PavelicV, MatterMS, OchsenbeinAF: Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells.Blood113 , 4681–4689 (2009).
  • Humlová Z , KlamováH, JanatkováIet al.: Immunological profiles of patients with chronic myeloid leukaemia I. State before the start of treatment.Folia Biol. Prague)52 , 47–58 (2006).
  • Reuschenbach M , von Knebel-Doeberitz M, Wentzensen N: A systemic review of humoral immune responses against tumor antigens. Cancer Immunol. Immunother.58 , 1535–1544 (2009).
  • De Gruijl TD , van der Eertwegh AJ, Pinedo HM, Scheper RJ: Whole-cell cancer vaccination: from autologous to allogenic tumor- and dendritic cell-based vaccines. Cancer Immunol. Immunother.57 , 1569–1577 (2008).
  • Michor F , HughesTP, IwasaYet al.: Dynamics of chronic myeloid leukaemiaNature435 , 1267–1270 (2005).
  • Abbott LH , MichorF: Mathematical models of targeted cancer therapy.Br. J. Cancer95 , 1136–1141 (2006).
  • Graham SM , JorgensenHG, AllanEet al.: Primitive quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia cells are insensitive to STI571 in vitro.Blood99 , 319–325 (2002).
  • Roeder I , HornM, GlaucheI, HochausA, MuellerMC, LoefflerM: Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implicationsNat. Med.12 , 1181–1184 (2006).
  • Chávez-Gonzáles A , Ayala-SánchezM, Sánchez-ValleEet al.: Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved haematological remission after different therapeutic procedures.Leuk. Res.30 , 286–295(2006).
  • Glauche I , HornM, RoederI: Leukemia stem cells: hit or miss?Br. J. Cancer96 , 677–678 (2007).
  • Komarova NL , WodarzD: Drug resistance in cancer. Principles of emergence and prevention.Proc. Natl Acad. Sci. USA102 , 9714–9719 (2005).
  • Guo XY , CuillerotT, WangTet al.: Peptide containing the BCR oligomerization domain (AA 1–160) reverses the transformed phenotype of p210bcr–abl positive 32D myeloid leukemia cells.Oncogene17 , 825–833 (1998).
  • Tolcher AW , MitaA, LewisLDet al.: Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.J. Clin. Oncol.26 , 5198–5203 (2008).
  • Tolcher A : Targeting Bcl-2 protein expression in solid tumors and haematological malignancies with antisense oligonucleotides.Clin. Adv. Hematol. Oncol.3 , 635–642 (2005).
  • Jayanthan A , HowardSC, TrippettTet al.: Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.Leuk. Lymphoma50 , 1069–1072 (2009).
  • Ochi T , FujiwaraH, SuemoriKet al.: Aurora-A kinase: a novel target of cellular immunotherapy for leukaemia.Blood113 , 66–74 (2008).
  • Chen CI , MaeckerHT, LeePP: Development and dynamics of robust T cell response to CML under imatinib treatment.Blood111 , 5342–5349 (2008).
  • Kim PS , LeePP, LevyD: Dynamics and potential impact of the immune response to chronic myelogenous leukemia.PLoS Comput. Biol.4 , E1000095 (2008).
  • Pinilla-Ibarz J , CathcartK, KorontsvitTet al.: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.Blood95 , 1781–1787 (2000).
  • Takahashi T , TanakaY, NiedaMet al.: Dendritic cell vaccination for patients with chronic myelogenous leukemia.Leuk. Res.27 , 795–802 (2003).
  • Ossenkoppele GJ , StamAG, WestersTMet al.: Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemia dendritic cells.Leukemia17 , 1424–1426 (2003).
  • Heslop HE , StevensonFK, MolldremJJ: Immunotherapy of hematologic malignancy.Hematology Am. Soc. Hematol. Educ. Program331–349 (2003).
  • Cathcart K , Pinilla-IbarzJ, KorontsvitTet al.: A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.Blood103 , 1037–1042 (2004).
  • Bocchia M , GentiliS, AbruzzeseEet al.: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.Lancet365 , 657–662 (2005).
  • Li Z , QiaoY, LiuBet al.: Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.Clin. Cancer Res.11 , 4460–4468 (2005).
  • Rojas JM , KnightK, WangL, ClarkRE: Clinical evaluation of BCR–ABL peptide immunisation in chronic myeloid leukemia: results of the EPIC study.Leukemia21 , 2287–2295 (2007).
  • Westermann J , KoopJ, van Lessen A et al.: Vaccination with autologous non-irradiated dendritic cells in patients with bcr-abl+ chronic myeloid leukemia. Br. J. Hematol.137 , 297–306 (2007).
  • Rezvani K , YongAS, MielkeS et al: Leukemia-associated antigen-specific T cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood111 , 236–242 (2008).
  • Jain N , ReubenJM, KantarjianHet al.: Synthetic tumor-specific breakpoint vaccine in patients with chronic myeloid leukaemia and minimal residual disease: a Phase 2 trial.Cancer115 , 3924–3934 (2009).
  • Maslak PG , DaoT, GomezMet al.: A pilot vaccination trial of synthetic analog peptides derived from the BCR–ABL breakpoints in CML patients with minimal disease.Leukemia22 , 1613–1616 (2008).
  • Bellantuono I , GaoL, ParryS et al: Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood100 , 3835–3837 (2002).
  • Millerem JJ , LeePP, WangC, ChamplinRE, DavisMM: A Pr1- human antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelologenous leukemia.Cancer Res.59 , 2675–2681 (1999).
  • Schmitt M , LiL, GiannopoulosKet al.: Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking co-stimulatory molecules.Exp. Hematol.34 , 1709–1719 (2006).
  • Yong AS , KeyvanfarK, EniafeRet al.: Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukaemia-associated antigens: implications for the graft-versus-leukemia effects and peptide vaccine based immunotherapy.Leukemia22 , 1721–1727 (2008).
  • Fujiwara H , MelenhortsJJ, OuriaghliFet al.: In vitro induction of myeloid leukaemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins.Clin. Cancer Res.11 , 4495–4503 (2005).
  • Adams SP , SahotaSS, MilovicA et al: Frequent expression of HAGE in presentation chronic myeloid leukemias. Leukemia16 , 2238–2242 (2002).
  • Riley CL , MathieuMG, ClarkRE, McArdleSE, ReesR: Tumour antigen-targeted immunotherapy for chronic myeloid leukemia: is it still viable?Cancer Immunol. Immunother.58 , 1489–1499 (2009).
  • Rezvani K , YongAS, TawabAet al.: Ex vivo characterization of polyclonal memory CD8+ T cell responses to PRAME- specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.Blood113 , 2245–2255 (2009).
  • Kessler JH , BeekmanNJ, Bres-VloemansSAet al.: Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.J. Exp. Med.193 , 73–88 (2001).
  • Quintarelli C , DottiG, DeAngelisBet al.: Cytoxic T lymphocytes directed to the perefertially expressed antigen of melanoma (PRAME) target chronic myelod leukemia.Blood112 , 1876–1885 (2008).
  • Ochi T , FujiwaraH, SuemoriKet al.: Aurora-A kinase: a novel target of cellular immunotherapy for leukemia.Blood113 , 66–74 (2009).
  • Han JF , ZhaoTT, LiuHLet al.: Identification of a new HLA-A 0201-restricted cytotoxic T. lymphocyte epitope from CLM28.Cancer Immunol. Immunother.55 , 1575–1583 (2006)
  • Suemori K , FujiwaraH, OchiTet al.: Identification of an epitope derived from CML 66 a novel tumor-associated antigen expressed broadly in human leukaemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymhocytes.Cancer Sci.99 , 1414–1419 (2008).
  • Chen J , SchmittA, BunjesD et al: The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogenic stem cell transplantation. Int. J. Oncol.30 , 1119–1127 (2007).
  • Hernández-Boluda JC , BellosilloB, VelaMC, ColomerD, Alvarez-LarránA, CervantesF: Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients.Leuk. Lymphoma46 , 717–722(2005).
  • Zeis M , SiegelS, WagnerAet al.: Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.J. Immunol.170 , 5391–5397 (2003).
  • Tschiedel S , GentiliniC, LangeTet al.: Indentification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.Leukemia22 , 1542–1550 (2008).
  • Andersen MH , SvaneIM, KvistborgPet al.: Immunogenicity of Bcl-2 in patients with cancer.Blood105 , 728–734 (2004).
  • Andersen MH , RekerS, KvistborgP, BeckerJC, thor Straten P: Spontaneous immunity against Bcl-xL in cancer patients. J. Immunol.175 , 2709–2714 (2005).
  • Greiner J , SchmittM, LiLet al.: Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches.Blood108 , 4109–4117 (2006).
  • Schmidt SM , SchagK, MüllerMRet al.: Induction of adipophillin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.Cancer Res.64 , 1164–1170 (2004).
  • Aqui NA , VonderheideRH: Survinin as a universal tumor antigen for novel cancer immunotherapy.Cancer Biol. Ther.1888–1889 (2008).
  • Smith BD , KasamonYL, KowalskiJ, GockeC, MurphyK, MillerCB: K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disese on imatinib mesylate.Clin. Cancer Res.16 , 338–347 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.